APOE and Alzheimer disease: Future therapeutic development and preclinical evaluation for AD should rigorously incorporate APOE allele profiling to assess intervention‐specific risk–benefit ratios, thereby minimizing iatrogenic exacerbation of neuropathological trajectories.